Cargando…
Immunologic response among HIV-infected patients enrolled in a graduated cost-recovery programme of antiretroviral therapy delivery in Chennai, India
BACKGROUND & OBJECTIVES: Sustainability of free antiretroviral therapy (ART) roll out programmes in resource-limited settings is challenging given the need for lifelong therapy and lack of effective vaccine. This study was undertaken to compare treatment outcomes among HIV-infected patients enro...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3734719/ https://www.ncbi.nlm.nih.gov/pubmed/23852295 |
_version_ | 1782279577156976640 |
---|---|
author | Solomon, Sunil Suhas Ganesh, Aylur K. Mehta, Shruti H. Yepthomi, Tokugha Balaji, Kavitha Anand, Santhanam Gallant, Joel E. Solomon, Suniti |
author_facet | Solomon, Sunil Suhas Ganesh, Aylur K. Mehta, Shruti H. Yepthomi, Tokugha Balaji, Kavitha Anand, Santhanam Gallant, Joel E. Solomon, Suniti |
author_sort | Solomon, Sunil Suhas |
collection | PubMed |
description | BACKGROUND & OBJECTIVES: Sustainability of free antiretroviral therapy (ART) roll out programmes in resource-limited settings is challenging given the need for lifelong therapy and lack of effective vaccine. This study was undertaken to compare treatment outcomes among HIV-infected patients enrolled in a graduated cost-recovery programme of ART delivery in Chennai, India. METHODS: Financial status of patients accessing care at a tertiary care centre, YRGCARE, Chennai, was assessed using an economic survey; patients were distributed into tiers 1- 4 requiring them to pay 0, 50, 75 or 100 per cent of their medication costs, respectively. A total of 1754 participants (ART naïve = 244) were enrolled from February 2005-January 2008 with the following distribution: tier 1=371; tier 2=338; tier 3=693; tier 4=352. Linear regression models with generalized estimating equations were used to examine immunological response among patients across the four tiers. RESULTS: Median age was 34; 73 per cent were male, and the majority were on nevirapine-based regimens. Median follow up was 11.1 months. The mean increase in CD4 cell count within the 1(st) three months of HAART was 50.3 cells/μl per month in tier 1. Compared to those in tier 1, persons in tiers 2, 3 and 4 had comparable increases (49.7, 57.0, and 50.9 cells/μl per month, respectively). Increases in subsequent periods (3-18 and >18 months) were also comparable across tiers. No differential CD4 gains across tiers were observed when the analysis was restricted to patients initiating ART under the GCR programme. INTERPRETATION & CONCLUSIONS: This ART delivery model was associated with significant CD4 gains with no observable difference by how much patients paid. Importantly, gains were comparable to those in other free rollout programmes. Additional cost-effectiveness analyses and mathematical modelling would be needed to determine whether such a delivery programme is a sustainable alternative to free ART programmes. |
format | Online Article Text |
id | pubmed-3734719 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-37347192013-08-08 Immunologic response among HIV-infected patients enrolled in a graduated cost-recovery programme of antiretroviral therapy delivery in Chennai, India Solomon, Sunil Suhas Ganesh, Aylur K. Mehta, Shruti H. Yepthomi, Tokugha Balaji, Kavitha Anand, Santhanam Gallant, Joel E. Solomon, Suniti Indian J Med Res Original Article BACKGROUND & OBJECTIVES: Sustainability of free antiretroviral therapy (ART) roll out programmes in resource-limited settings is challenging given the need for lifelong therapy and lack of effective vaccine. This study was undertaken to compare treatment outcomes among HIV-infected patients enrolled in a graduated cost-recovery programme of ART delivery in Chennai, India. METHODS: Financial status of patients accessing care at a tertiary care centre, YRGCARE, Chennai, was assessed using an economic survey; patients were distributed into tiers 1- 4 requiring them to pay 0, 50, 75 or 100 per cent of their medication costs, respectively. A total of 1754 participants (ART naïve = 244) were enrolled from February 2005-January 2008 with the following distribution: tier 1=371; tier 2=338; tier 3=693; tier 4=352. Linear regression models with generalized estimating equations were used to examine immunological response among patients across the four tiers. RESULTS: Median age was 34; 73 per cent were male, and the majority were on nevirapine-based regimens. Median follow up was 11.1 months. The mean increase in CD4 cell count within the 1(st) three months of HAART was 50.3 cells/μl per month in tier 1. Compared to those in tier 1, persons in tiers 2, 3 and 4 had comparable increases (49.7, 57.0, and 50.9 cells/μl per month, respectively). Increases in subsequent periods (3-18 and >18 months) were also comparable across tiers. No differential CD4 gains across tiers were observed when the analysis was restricted to patients initiating ART under the GCR programme. INTERPRETATION & CONCLUSIONS: This ART delivery model was associated with significant CD4 gains with no observable difference by how much patients paid. Importantly, gains were comparable to those in other free rollout programmes. Additional cost-effectiveness analyses and mathematical modelling would be needed to determine whether such a delivery programme is a sustainable alternative to free ART programmes. Medknow Publications & Media Pvt Ltd 2013-06 /pmc/articles/PMC3734719/ /pubmed/23852295 Text en Copyright: © The Indian Journal of Medical Research http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Solomon, Sunil Suhas Ganesh, Aylur K. Mehta, Shruti H. Yepthomi, Tokugha Balaji, Kavitha Anand, Santhanam Gallant, Joel E. Solomon, Suniti Immunologic response among HIV-infected patients enrolled in a graduated cost-recovery programme of antiretroviral therapy delivery in Chennai, India |
title | Immunologic response among HIV-infected patients enrolled in a graduated cost-recovery programme of antiretroviral therapy delivery in Chennai, India |
title_full | Immunologic response among HIV-infected patients enrolled in a graduated cost-recovery programme of antiretroviral therapy delivery in Chennai, India |
title_fullStr | Immunologic response among HIV-infected patients enrolled in a graduated cost-recovery programme of antiretroviral therapy delivery in Chennai, India |
title_full_unstemmed | Immunologic response among HIV-infected patients enrolled in a graduated cost-recovery programme of antiretroviral therapy delivery in Chennai, India |
title_short | Immunologic response among HIV-infected patients enrolled in a graduated cost-recovery programme of antiretroviral therapy delivery in Chennai, India |
title_sort | immunologic response among hiv-infected patients enrolled in a graduated cost-recovery programme of antiretroviral therapy delivery in chennai, india |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3734719/ https://www.ncbi.nlm.nih.gov/pubmed/23852295 |
work_keys_str_mv | AT solomonsunilsuhas immunologicresponseamonghivinfectedpatientsenrolledinagraduatedcostrecoveryprogrammeofantiretroviraltherapydeliveryinchennaiindia AT ganeshaylurk immunologicresponseamonghivinfectedpatientsenrolledinagraduatedcostrecoveryprogrammeofantiretroviraltherapydeliveryinchennaiindia AT mehtashrutih immunologicresponseamonghivinfectedpatientsenrolledinagraduatedcostrecoveryprogrammeofantiretroviraltherapydeliveryinchennaiindia AT yepthomitokugha immunologicresponseamonghivinfectedpatientsenrolledinagraduatedcostrecoveryprogrammeofantiretroviraltherapydeliveryinchennaiindia AT balajikavitha immunologicresponseamonghivinfectedpatientsenrolledinagraduatedcostrecoveryprogrammeofantiretroviraltherapydeliveryinchennaiindia AT anandsanthanam immunologicresponseamonghivinfectedpatientsenrolledinagraduatedcostrecoveryprogrammeofantiretroviraltherapydeliveryinchennaiindia AT gallantjoele immunologicresponseamonghivinfectedpatientsenrolledinagraduatedcostrecoveryprogrammeofantiretroviraltherapydeliveryinchennaiindia AT solomonsuniti immunologicresponseamonghivinfectedpatientsenrolledinagraduatedcostrecoveryprogrammeofantiretroviraltherapydeliveryinchennaiindia |